Effect of adiponectin and sex steroid hormones on bone mineral density and bone formation markers in postmenopausal women with subclinical hyperthyroidism

2010 ◽  
Vol 36 (2) ◽  
pp. 370-376 ◽  
Author(s):  
Ki Hoon Ahn ◽  
Seung Hyeun Lee ◽  
Hyun Tae Park ◽  
Tak Kim ◽  
Jun Young Hur ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Steroid Hormones ◽  
Bone Mineral ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Subclinical Hyperthyroidism ◽  
Mineral Density ◽  
Bone Formation Markers

scholarly journals Sex steroid hormones, bone mineral density, and risk of breast cancer.

1997 ◽  
Vol 105 (suppl 3) ◽  
pp. 593-599 ◽  
Author(s):  
L H Kuller ◽  
J A Cauley ◽  
L Lucas ◽  
S Cummings ◽  
W S Browner
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Steroid Hormones ◽  
Bone Mineral ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Mineral Density

scholarly journals Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

2008 ◽  
Vol 93 (3) ◽  
pp. 852-860 ◽  
Author(s):  
Steven Boonen ◽  
Fernando Marin ◽  
Barbara Obermayer-Pietsch ◽  
Maria E. Simões ◽  
Clare Barker ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Antiresorptive Therapy ◽  
Mineral Density ◽  
Teriparatide Treatment ◽  
Bone Formation Markers ◽  
Hip Bmd

Abstract Introduction: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 μg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr. Methods: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n = 107), risedronate (n = 59), etidronate (n = 30), and non-bisphosphonate (n = 49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months. Results: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide. Conclusions: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.

scholarly journals Sex Steroid Hormones in Older Men: Longitudinal Associations with 4.5-Year Change in Hip Bone Mineral Density—The Osteoporotic Fractures in Men Study

2010 ◽  
Vol 95 (9) ◽  
pp. 4314-4323 ◽  
Author(s):  
Jane A. Cauley ◽  
Susan K. Ewing ◽  
Brent C. Taylor ◽  
Howard A. Fink ◽  
Kristine E. Ensrud ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Steroid Hormones ◽  
Sex Hormones ◽  
Bone Mineral ◽  
Older Men ◽  
Sex Steroid Hormones ◽  
Mass Action ◽  
Sex Steroid ◽  
Mineral Density ◽  
Hip Bmd

Context: There is limited information on the association between sex hormones and bone loss in older men. Objective: Our objective was to determine the longitudinal association between sex steroid hormones and bone mineral density (BMD). Design and Setting: We conducted a prospective study of 5995 men aged at least 65 yr old at six U.S. clinical centers. Participants: Sex steroid hormones were measured in a random sample of 1602 men. After exclusions, 1238 men were included in cross-sectional analyses and 969 in longitudinal analyses. Baseline sex hormones were measured using liquid chromatography-mass spectrometry. Bioavailable (Bio) estradiol (BioE2) and testosterone (BioT) were calculated from mass action equations. SHBG was measured using chemiluminescent substrate. Main Outcome Measures: BMD of the total hip, measured at baseline and once or twice afterward over 4.6 yr of follow-up, was evaluated. Results: The annualized percent change in hip BMD increased with decreasing BioE2 (P trend = 0.03). Men with the lowest BioE2 (<39.7 pmol/liter) compared with the highest BioE2 (≥66.0 pmol/liter) experienced 38% faster rate of BMD loss (P < 0.05). There was no association between BioT and hip BMD loss. Men with lowest BioE2, lowest BioT, and highest SHBG experienced a 3-fold faster rate of BMD loss compared with men with higher levels (P = 0.02). A threshold effect of SHBG was observed; the rate of hip BMD loss increased in men with SHBG of 49–60 nm. Conclusions: Low BioE2 and high SHBG levels were associated with lower BMD and faster hip BMD loss. The combination of low BioE2, low BioT, and high SHBG was associated with significantly faster rates of BMD loss.

scholarly journals Sex Steroid Hormones, Bone Mineral Density, and Risk of Breast Cancer

1997 ◽  
Vol 105 ◽  
pp. 593 ◽  
Author(s):  
Lewis H. Kuller ◽  
Jane A. Cauley ◽  
Lee Lucas ◽  
Steve Cummings ◽  
Warren S. Browner
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Steroid Hormones ◽  
Bone Mineral ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Mineral Density

scholarly journals Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men

2009 ◽  
Vol 70 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Channing J. Paller ◽  
Meredith S. Shiels ◽  
Sabine Rohrmann ◽  
Shehzad Basaria ◽  
Nader Rifai ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Steroid Hormones ◽  
Bone Mineral ◽  
Representative Sample ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Mineral Density ◽  
Nationally Representative ◽  
Relationship Of

scholarly journals Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey

2011 ◽  
Vol 10 (3) ◽  
pp. 1999-2008 ◽  
Author(s):  
M.B. Yilmaz ◽  
A. Pazarbasi ◽  
A.I. Guzel ◽  
S. Kocaturk-Sel ◽  
H. Kasap ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Gene Polymorphisms ◽  
Sex Steroid ◽  
Mineral Density ◽  
Cyp19 Gene

scholarly journals Bone mineral density and bone metabolism in postmenopausal women with type 2 diabetes in a Chinese community: a cross-sectional study

2020 ◽  
Author(s):  
Wu Han ◽  
Yufan Zhang ◽  
Wenbin Zhou ◽  
Jing Dai ◽  
Tao Yao ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Bone Formation ◽  
Bone Turnover ◽  
Bone Metabolism ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Mineral Density ◽  
Osteoporosis Fracture

Abstract AMI: There is growing evidence of a complex interaction between T2DM and osteoporosis. The purpose of this study was to further study the relationship between BTMs and fasting blood glucose (FBG) in postmenopausal patients with type 2 diabetes and to analyze the effect of hyperglycemia on bone metabolism. Methods: Six hundred and twelve (612) postmenopausal women were included, including one hundred and seven (107) subjects with T2DM and five hundred and five (505) subjects without diabetes. BMD was measured by DXA (dual-energy X-ray absorptiometry). Markers of bone formation (P1NP) and resorption ( CTX ) were quantified. Results: Compared to controls, postmenopausal women with diabetes had a higher prevalence of previous osteoporosis fracture (27.1% vs. 17.4% for diabetic and nondiabetic women, respectively) and a higher BMD. The P1NP level in women with T2DM was 49.451 ng/ml, while in N-DM individuals, it was 58.633 ng/ml, (p = 0.017). The CTX level in women with T2DM was 0.325 ng/ml, while in N-DM individuals, it was 0.412 ng/ml (p=0.039). In addition, P1NP was significantly negatively associated with age (β=-0.590; p= 0.002) and FBG (β=-1.950; p = 0.035). CTX was negatively associated with FBG (β=-0.029; p = 0.015). Conclusions: T2DM was associated with higher BMD and paradoxically, with an increased risk of fracture. Postmenopausal women with T2DM had lower bone turnover than controls. With increased levels of FBG, bone formation and bone resorption were reduced, and the overall bone turnover level was reduced. Keywords Type 2 diabetes mellitus · Bone mineral density · Bone turnover markers · Osteoporosis fracture

Sign in / Sign up

Export Citation Format

Share Document